AstraZeneca
AZN
#52
Rank
A$408.52 B
Marketcap
A$263.41
Share price
-0.60%
Change (1 day)
-6.83%
Change (1 year)

P/E ratio for AstraZeneca (AZN)

P/E ratio as of November 2026 (TTM): 24.7

According to AstraZeneca's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.691. At the end of 2024 the company had a P/E ratio of 28.0.

P/E ratio history for AstraZeneca from 2009 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202428.0-16.41%
202333.5-44.38%
202260.3-83.53%
2021366892.33%
202036.9-56.62%
201985.0135.02%
201836.264.78%
201722.046.96%
201614.9-32.66%
201522.2-56.3%
201450.8163.94%
201319.2202.22%
20126.3650.63%
20114.22

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
40.7 64.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
28.9 17.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
38.9 57.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
38.5 55.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
43.8 77.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
23.6-4.24%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
106 329.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
136 449.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
13.1-47.00%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
16.7-32.23%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.